Core Viewpoint - The company, Chongqing Huason Pharmaceutical Co., Ltd., has announced its 2025 semi-annual profit distribution plan, which includes a cash dividend of RMB 0.35 per 10 shares for all shareholders, totaling approximately RMB 14.62 million [2][5]. Profit Distribution Plan - The profit distribution plan was approved by the board on August 21, 2025, following authorization from the 2024 annual shareholders' meeting held on May 21, 2025 [1][3]. - The total share capital as of June 30, 2025, is 417,596,314 shares, serving as the basis for the cash distribution [2][5]. - The distribution will not involve stock increases or bonus shares, and any undistributed profits will be carried forward to future distributions [2][5]. Taxation Details - The cash dividend of RMB 0.35 per 10 shares is subject to tax, with different rates applied based on the type of shareholder and holding period [5]. - For Hong Kong market investors and certain foreign institutions, the net cash distribution will be RMB 0.315 per 10 shares after tax [5]. Key Dates - The record date for the distribution is set for September 8, 2025, and the ex-dividend date is September 9, 2025 [5]. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies on the ex-dividend date [7].

Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has announced its profit distribution plan for the first half of 2025, which includes a cash dividend of RMB 0.35 per 10 shares, totaling approximately RMB 14.62 million, to be distributed to all shareholders [1][2]. Profit Distribution Plan - The profit distribution plan was approved at the fourth board meeting on August 21, 2025, with the total share base being 417,596,314 shares [1][2]. - The cash dividend will be distributed as follows: RMB 0.35 per 10 shares (before tax) for all shareholders, while specific tax rates apply for different categories of investors [2]. Dividend Payment Dates - The record date for the dividend distribution is set for September 8, 2025, and the ex-dividend date is September 9, 2025 [2]. Distribution Recipients - The recipients of the dividend will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [3]. Distribution Method - Cash dividends for A-share shareholders will be directly credited to their accounts through their securities companies on the ex-dividend date [3]. - The company will bear all legal responsibilities if there are any discrepancies in the dividend distribution due to changes in shareholders' accounts during the application period [3]. Reference Documents - The announcement includes references to the resolutions from the 2024 annual general meeting and the second meeting of the fourth board of directors, along with confirmation documents from the China Securities Depository and Clearing Corporation [4].

Core Points - Huason Pharmaceutical announced a cash dividend distribution plan for the first half of 2025, proposing a payment of 0.35 RMB per 10 shares to all shareholders [2] Summary by Category - **Dividend Distribution** - The total share capital of the company is 417,596,314 shares, which serves as the basis for the dividend distribution [2] - The record date for the dividend is set for September 8, 2025, and the ex-dividend date is September 9, 2025 [2]

证券代码：002907 证券简称：华森制药 公告编号：2025-071 重庆华森制药股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据 2024 年年度股东大会授权，重庆华森制药股份有限公司（以下简称"公司"） 2025 年半年度权益分派方案已获 2025 年 8 月 21 日召开的第四届董事会第二次会议审 议通过，现将权益分派事宜公告如下： 一、利润分配方案审议情况 1.2025 年 5 月 21 日，公司召开 2024 年年度股东大会审议通过了《关于授权董事 会制定 2025 年中期分红方案的议案》，授权董事会根据股东大会决议在符合利润分 配的条件下制定具体的中期分红方案。2025 年 8 月 21 日，公司召开第四届董事会第 二次会议审议通过了《关于公司〈2025 年半年度利润分配预案〉的议案》，具体内容 详见公司分别于 2025 年 5 月 22 日、2025 年 8 月 22 日刊登在《中国证券报》《上海 证券报》《证券日报》《证券时报》和巨潮资讯网（www.cninfo.com.cn）的《2024 ...

Core Viewpoint - The increasing prevalence of throat diseases due to environmental pollution, lifestyle changes, and an aging population is driving the demand for throat traditional Chinese medicine (TCM), with the market expected to reach 7.4 billion yuan in 2024, reflecting a year-on-year growth of 7.49% [1][9]. Overview - Throat diseases are primarily caused by various factors such as wind-heat invasion and internal heat, leading to symptoms like sore throat and hoarseness. Throat TCM is made from traditional Chinese medicinal ingredients and is used to treat throat-related ailments, characterized by stable efficacy and minimal side effects [1][3]. Development History - The throat medicine industry in China began relatively late, with significant advancements in chronic pharyngitis research in the 1980s leading to the development of throat medications. The market was initially fragmented, but the introduction of products like Guangxi Jinsongzi's throat lozenges in 1995 marked a turning point, establishing a competitive landscape [4][5]. Market Policy - The Chinese government has implemented various policies to support the development of the TCM industry, creating a favorable environment for throat TCM growth. These include measures to enhance TCM regulation and promote innovation [5][6]. Industry Chain - The throat TCM industry consists of an upstream segment focused on medicinal herb cultivation, a midstream segment for manufacturing, and a downstream segment involving sales through medical institutions, pharmacies, and e-commerce platforms. The primary consumer groups include individuals who use their voices frequently and patients with chronic throat conditions [6][7][8]. Current Market Situation - The throat TCM market is experiencing rapid growth, with a projected sales figure of 7.4 billion yuan in 2024. Tablets represent the largest segment at 41.65%, followed by granules and pills [1][9]. Competitive Landscape - The throat TCM market is characterized by high concentration, with the top five companies holding over 50% market share in retail pharmacies. Guangxi Jinsongzi leads with a market share of 16.95% [10][11]. Key Companies - Guangxi Jinsongzi Group is a major player in the throat TCM market, with a projected revenue of 1.185 billion yuan in 2024 and a gross profit margin of 75.46% [12]. - Guilin Sanjin Pharmaceutical Co., Ltd. is another key player, with a projected revenue of 2.194 billion yuan in 2024 and a gross profit margin of 73.41% [12]. Future Trends - The throat TCM industry is expected to focus on improving the quality of raw materials and production processes to meet rising consumer demands for high-quality products. Additionally, there is potential for international market expansion, particularly in Southeast Asia, as awareness and acceptance of TCM grow [13].

金融界消息 截至2025年8月25日收盘，华森制药（002907）报收于18.4元，下跌0.38%，换手率3.33%， 成交量9.99万手，成交金额1.84亿元。 通过天眼查大数据分析，重庆华森制药股份有限公司共对外投资了12家企业，参与招投标项目4258次， 知识产权方面有商标信息204条，专利信息135条，此外企业还拥有行政许可207个。 资金流向方面，今日主力资金净流出1278.91万元，占比成交额6.97%。其中，超大单净流出448.79万 元、占成交额2.45%，大单净流出830.12万元、占成交额4.52%，中单净流出流出80.89万元、占成交额 0.44%，小单净流入1359.80万元、占成交额7.41%。 来源：金融界 华森制药最新一期业绩显示，截至2025中报，公司营业总收入4.42亿元、同比增长5.76%，归属净利润 5395.05万元，同比增长14.27%，扣非净利润4675.48万元，同比增长12.52%，流动比率4.242、速动比率 3.771、资产负债率15.43%。 天眼查商业履历信息显示，重庆华森制药股份有限公司，成立于1996年，位于重庆市，是一家以从事医 药制造业为主的企业 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-070 重庆华森制药股份有限公司 关于公司产品完成境内生产药品备案的公告 （一）延长药品有效期申请 1.阿戈美拉汀片 药 品 通 用 名 称：阿戈美拉汀片 备 案 号：渝备 2025029865 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日从国家药品监督管 理局（以下简称"国家药监局"）网站查询获知公司产品阿戈美拉汀片完成境内 生产药品备案（延长药品有效期申请），并于国家药监局网站公示备案信息。现 将相关情况公告如下： 一、药品基本信息 药 品 批 准 文 号 / 原 料 药 登 记 号 ：国药准字 Z20249539 上 市 许 可 持 有 人：重庆华森制药股份有限公司 上市许可持有人地址：重庆市荣昌区工业园区 阿戈美拉汀项目为公司原料药制剂一体化项目。根据药智网数据，2024 年 阿戈美拉汀片整体市场份额为 7.9 亿元。该药品是一种新型抗抑郁药物，其作用 机制突破了传统单胺类递质系统，通过激活褪黑素受体（MT1 和 MT2）以及拮抗 5- ...

Core Viewpoint - Huason Pharmaceutical (002907) reported a solid performance in its 2025 mid-year financial results, with revenue and net profit showing significant year-on-year growth, indicating improved profitability and operational efficiency [1] Financial Performance - Total revenue for the first half of 2025 reached 442 million yuan, a year-on-year increase of 5.76% [1] - Net profit attributable to shareholders was 53.95 million yuan, up 14.27% from the previous year [1] - In Q2 2025, total revenue was 203 million yuan, reflecting a 7.13% increase year-on-year, while net profit surged by 98.08% to 13.60 million yuan [1] - Gross margin improved to 58.74%, an increase of 1.47% year-on-year, and net margin rose to 11.83%, up 4.71% [1] - Total expenses (selling, administrative, and financial) amounted to 160 million yuan, accounting for 36.09% of revenue, a decrease of 2.07% year-on-year [1] Key Financial Metrics - Earnings per share (EPS) increased to 0.13 yuan, a rise of 14.24% year-on-year [1] - Cash flow from operating activities per share decreased to 0.07 yuan, down 57.49% year-on-year [1] - The company's net asset value per share was 4.03 yuan, up 2.44% from the previous year [1] Significant Changes in Financial Items - Cash and cash equivalents decreased by 37.67% due to increased investments in financial products [3] - Long-term equity investments dropped by 100% as the company gained control over a previously associated enterprise [4] - Other current assets increased by 171.49% due to the purchase of financial products [5] - Employee compensation liabilities decreased by 61.8% as year-end bonuses were paid out [6] Business Model and Operational Insights - The company's performance is primarily driven by research and marketing efforts, necessitating a thorough examination of these underlying drivers [7] - The accounts receivable situation is concerning, with accounts receivable to profit ratio reaching 276.43% [7]

Core Insights - Huason Pharmaceutical (002907.SZ) reported a total operating revenue of 442 million yuan for the first half of 2025, an increase of 24.06 million yuan compared to the same period last year, marking a year-on-year growth of 5.76% [1] - The net profit attributable to shareholders reached 53.95 million yuan, up by 6.74 million yuan from the previous year, reflecting a year-on-year increase of 14.27% [1] - The company achieved a net cash inflow from operating activities of 27.53 million yuan [1] Financial Metrics - The latest debt-to-asset ratio stands at 15.43% [3] - The gross profit margin is 58.74%, which is an increase of 0.85 percentage points from the same period last year [3] - Return on equity (ROE) is reported at 3.20%, up by 0.33 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.13 yuan, an increase of 0.02 yuan compared to the same period last year, representing a year-on-year growth of 14.24% [3] - The total asset turnover ratio is 0.22 times, remaining stable compared to the previous year [3] - The inventory turnover ratio is 1.40 times, an increase of 0.17 times year-on-year, reflecting a growth of 14.09% [3] Shareholder Structure - The number of shareholders is reported at 32,800, with the top ten shareholders holding a total of 326 million shares, accounting for 78.09% of the total share capital [3] - The largest shareholder is Chengdu Local Construction Machinery Engineering Co., Ltd., holding 40.49% of the shares [3] - Other significant shareholders include You Hongtao (17.34%), Wang Ying (8.76%), and Liu Xiaoying (8.60%) [3]

所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 登录新浪财经APP 搜索【信披】查看更多考评等级 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 □是 √否 公司经本次董事会审议通过的利润分配预案为：以2025年6月30日登记的总股本417,596,314股为基数， 向全体股东每10股派发现金红利0.35元（含税），送红股0股（含税），不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 3、公司股东数量及持股情况 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 √不适用 □适 ...